Sponsored content brought to you by The advent of multiomic approaches has significantly improved early cancer detection by ...

Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of antibody–drug conjugates.

"The Custom Assay Development Kit is a direct response to the growing demand from researchers eager to harness our cutting-edge NULISA technology to develop high-performance biomarker assays for ...

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular ...

A groundbreaking AI-powered research platform, POETIC-AI, has been unveiled by scientists from The Institute of Cancer Research, promising to acc ...

The global US Biomarkers Market is expected to reach US$34.3 billion by 2029 from US$20.5 billion in 2024, at a CAGR of 10.8% during ...

The global brain biomarkers market is poised for remarkable growth, fueled by the escalating prevalence of neurological disorders and rapid technological advancements. A recent market analysis reveals ...

Feb. 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the NULISAqpcr™ Custom Assay ...

The TARGT First Solid test by Bengaluru-based 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, ...